Profile
International Journal of Pediatrics & Neonatal Care Volume 5 (2019), Article ID 5:IJPNC-152, 6 pages
https://doi.org/10.15344/2455-2364/2019/152
Case Study
Assessment of Risk Factors, which Affect the Presence of Inhibitors in Children with Hemophilia A: The Albanian Case-control Study

Arlind Deveja1, Donjeta Bali2, Mirela Xhafa2, Mirzana Kapllanaj2, Etleva Refatllari3 and Anila Godo4,*

1Department of Pediatrics, University Hospital Center ‘Mother Teresa’ Tirana, Albania
2Pediatric Hematologist/Oncologist, University Hospital Center ‘Mother Teresa’ Tirana, Albania
3Laboratory of Clinical Chemistry and Hematology, University Hospital Center ‘Mother Teresa’ Tirana, Albania
4Pediatric Hematologist/Oncologist, Chief of Department of Pediatrics, University Hospital Center ‘Mother Teresa’ Tirana
Dr. Anila Godo, Pediatric Hematologist/Oncologist, Chief of Department of Pediatrics, University Hospital Center ‘Mother Teresa’ Tirana, Albania; E-mail: godoanila@gmail.com
07 February 2019; 23 April 2019; 25 April 2019
Deveja A, Bali D, Xhafa M, Kapllanaj M, Refatllari E, et al. (2019) Assessment of Risk Factors, which Affect the Presence of Inhibitors in Children with Hemophilia A: The Albanian Case-control Study. Int J Pediatr Neonat Care 5: 152. doi: https://doi.org/10.15344/2455-2364/2019/152

Abstract

Our study was designed to describe the correlation between patient and therapy characteristics with inhibitors presence in Albanian pediatric patients who suffer from hemophilia A (previously treated more than 50 days with FVIII). We investigated all the pediatric (0-14 years old) patients of Albania with hemophilia A (45 patients were initially enrolled). The main outcome was the inhibitor presence, confirmed by our laboratory with qualitative test. The test was performed only in 32 of our patients (71% of population). Thirteen of them (40.6%) are positive for inhibitors presence; this finding is higher than the percentage, which is referred in other countries. We found an association between intensity of replacement therapy (time between first treatment with FVIII and the 50th treatment) (t=2.267; df=30; p=0.031), frequency of treatment until the 50th exposure day (t=3.270; df=30; p=0.003) and the average dosage of FVIII (χ2=12,799; df=2; p=0.002) with inhibitor presence. Also the length of exposure episode (more than 5 days) was correlated with the inhibitor presence (t=6.131; df=1; p=0.015). Breastfeeding was associated with lower risk for inhibitors presence (t=7.166; df=; p=0.011). In our study the severity of the disease, family history for hemophilia, age, reason of the first exposure and surgical treatment during the first 50 days of exposure were not significant statistical correlated. Our findings suggest that the aggressivity (intensity, frequency, dosage) of the replacement therapy with exogenous FVIII have a primary role in inhibitors presence or development.